← Back to patent-cliff list
恩曲他滨/富马酸磷丙替诺福韦
Tier B — Position earlyEmtricitabine/Tenofovir Alafenamide Fumarate
Gilead Inc
Originator
2016
First approval
-
Expiry (public)
$2.76B ▲
Peak sales
化学药
Type
Targets：RT、HIV-1 RT
Brand：Descovy
Indications (approved)：HIV感染
Regional status
US
批准上市
2016-04-04
EU
批准上市
2016-04-21
China
批准上市
2018-11-21
Japan
批准上市
2016-12-09
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Emtricitabine/Tenofovir Alafenamide Fumarate?
Approved indications include: HIV感染.
When does the Emtricitabine/Tenofovir Alafenamide Fumarate patent expire?
No public expiry year is available for Emtricitabine/Tenofovir Alafenamide Fumarate yet; this page updates once verified.
How do I get a quote for Emtricitabine/Tenofovir Alafenamide Fumarate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24